Form 8-K Amphastar Pharmaceutical For: Nov 08
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/19/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- SanDisk stock rallies on AI optimism and Fed relief
Amphastar Pharmaceuticals (AMPH) PT Raised to $23 at Piper Jaffray
November 9, 2017 7:52 AM ESTPiper Jaffray raised its price target on Amphastar Pharmaceuticals (NASDAQ: AMPH) to $23.00 (from $19.00) while maintaining an Overweight rating.
Analyst David Amsellem notes solid performance from the base business. The analyst believes there is still room for meaningful value creation in the context of an EV/2018E EBITDA of 10x-11x.
... More